Ozempic: Here’s why 2023’s star obesity treatment is causing headaches for CSL and several other biotech stocks
Ozempic is one of the few things giving CSL (ASX:CSL) shareholders sleepless nights right now. And you could argue this…
Read More
The ASX & SGX: Imagine if the proposed $8.4bn merger had actually gone ahead
Remember when the Singapore Exchange (SGX) made a A$8.4bn bid for the ASX? It was over a decade now, but we…
Read More
Rejecting a takeover offer: Here are 5 ASX stocks that did and how it ended for them
Rejecting a takeover offer is a bold step for an ASX company to take. It is turning down sweet quick…
Read More